Evidence map›Paper›PMID 37754131›Full record

ArticleBiosensors2023

Novel Cytochrome P450-3A4 Enzymatic Nanobiosensor for Lapatinib (a Breast Cancer Drug) Developed on a Poly(anilino-co-4-aminobenzoic Acid-Green-Synthesised Indium Nanoparticle) Platform.

Jaymi Leigh January, Ziyanda Zamaswazi Tshobeni, Nokwanda Precious Pearl Ngema, Abongile Nwabisa Jijana, Emmanuel Iheanyichukwu Iwuoha, Takalani Mulaudzi, Samantha Fiona Douman, Rachel Fanelwa Ajayi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jaymi Leigh JanuarySensorLab (UWC Sensor Laboratories), University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa.ORCID 0000-0002-2499-9934
Ziyanda Zamaswazi TshobeniSensorLab (UWC Sensor Laboratories), University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa.
Nokwanda Precious Pearl NgemaSensorLab (UWC Sensor Laboratories), University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa.
Abongile Nwabisa JijanaNanotechnology Innovation Centre, Advanced Materials Division, Mintek, Private Bag X3015, Randburg, Johannesburg 2125, South Africa.ORCID 0000-0002-4425-9386
Emmanuel Iheanyichukwu IwuohaSensorLab (UWC Sensor Laboratories), University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa.ORCID 0000-0001-6102-0433
Takalani MulaudziDepartment of Biotechnology, University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa.ORCID 0000-0002-5792-1973
Samantha Fiona DoumanDepartment of Chemistry, University of Cape Town, Private Bag X3, Rondebosch, Cape Town 7701, South Africa.
Rachel Fanelwa AjayiSensorLab (UWC Sensor Laboratories), University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa.ORCID 0000-0003-0899-433X
University of the Western Cape · ZAMintek · ZAUniversity of Cape Town · ZA

Funding

National Nanoscience Postgraduate Teaching and Training Platform n/a
6 · The paper itself

Abstract

Breast cancer (BC) is one of the most common types of cancer disease worldwide and it accounts for thousands of deaths annually. Lapatinib is among the preferred drugs for the treatment of breast cancer. Possible drug toxicity effects of lapatinib can be controlled by real-time determination of the appropriate dose for a patient at the point of care. In this study, a novel highly sensitive polymeric nanobiosensor for lapatinib is presented. A composite of poly(anilino-co-4-aminobenzoic acid) co-polymer {poly(ANI-co-4-ABA)} and coffee extract-based green-synthesized indium nanoparticles (InNPs) was used to develop the sensor platform on a screen-printed carbon electrode (SPCE), i.e., SPCE||poly(ANI-co-4-ABA-InNPs). Cytochrome P450-3A4 (CYP3A4) enzyme and polyethylene glycol (PEG) were incorporated on the modified platform to produce the SPCE||poly(ANI-co-4-ABA-InNPs)|CYP3A4|PEG lapatinib nanobiosensor. Experiments for the determination of the electrochemical response characteristics of the nanobiosensor were performed with cyclic voltammetry (CV) and differential pulse voltammetry (DPV). The nanobiosensor calibration for 0-100 ng/mL lapatinib was linear and gave limit of detection (LOD) values of 13.21 ng/mL lapatinib and 18.6 ng/mL lapatinib in physiological buffer and human serum, respectively. The LOD values are much lower than the peak plasma concentration (C

Indexed as

Antineoplastic AgentsBiosensing TechniquesBreast NeoplasmsNanoparticles4-Aminobenzoic AcidAnthracenesCytochrome P-450 CYP3AElectrochemical TechniquesElectrodesFemaleHumansIndiumLapatinibPharmaceutical Preparations4-(2-anthryl)butanoic acid4-Aminobenzoic AcidAnthracenesAntineoplastic AgentsCytochrome P-450 CYP3AIndiumLapatinibPharmaceutical Preparationsbiosensorbreast cancer drug (lapatinib)cytochrome P450-3A4green-synthesized indium nanoparticlespolyaniline

Identifiers

PMID37754131
PMCPMC10527071
OpenAlexW4386960287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.